Clinical Trials

Inclusion Criteria:

• Confirmed anhydramnios before 22 weeks GA for patients with FRF or confirmed diagnosis of CoBRA.
  • Anhydramnios in the absence of ruptured membranes (ROM) on ultrasound.
  • No significant bladder filling on ultrasound.
• Consent is signed and first therapeutic amnioinfusion can and does occur before 26 weeks and 0 days gestational age.
• Confirmation that the expectant mother does not wish to undergo termination of the pregnancy.
• Age ≥ 18 years of age for expectant mothers.
• Willingness to be followed and deliver at a RAFT center.
• Willingness for postnatal care to be performed at a RAFT center until discharge.
• Completed consults with Pediatric Nephrology, Neonatology, Transplant Surgery, Pediatric surgery, Maternal-Fetal Medicine Specialist, and Licensed Clinical Social Worker and a Genetic Counselor.

Exclusion Criteria:

• Cervix less than 2.5 cm in length.
• No significant pathogenic or likely significant pathogenic findings on Karyotype or Microarray.
• Other significant congenital anomalies in the fetus.
• Evidence of chorioamnionitis or abruptio placentae.
• Evidence of rupture of membranes or chorioamniotic separation.
• Evidence of preterm labor.
• Multiple gestation.
• Severe maternal medical condition in pregnancy.
• Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17 that is refractory to treatment.
• Technical limitations precluding amnioinfusion.